DNA PLC STOCK EXCHANGE RELEASE 22 March 2017 at 12:00 EET
DNA Plc's Annual General Meeting was held in Helsinki on 22 March 2017.
The AGM adopted the financial statements and discharged the Board of Directors and the CEO from liability for the financial period 2016.
Dividend was confirmed to be EUR 0.55 per share, EUR 72,766,925 in total, according to the Board proposal. The dividend will be paid to shareholders who are registered, on the dividend record date of 24 March 2017, in the company's register of shareholders held by Euroclear Finland Ltd. The dividend will be paid on 7 April 2017.
Board of Directors and auditor
The number of Board members was confirmed to be seven. Re-elected members of the Board include Pertti Korhonen, Anu Nissinen, Tero Ojanperä, Jukka Ottela, Margus Schults and Kirsi Sormunen. Heikki Mäkijärvi was elected a new member.
The AGM decided not to change the remunerations paid to the members of the Board of Directors. The Chairman of the Board will be paid annual remuneration of EUR 144,000, and each member will be paid EUR 48,000. Further, it was confirmed that the meeting fee per Board meeting will be EUR 1,050. The meeting fees of permanent committees of the Board were confirmed to be EUR 1,050 per meeting to Committee Chairs and EUR 525 to committee members.
The auditor will continue to be PricewaterhouseCoopers Oy, with Authorised Public Accountant Mika Kaarisalo acting as the principal auditor.
Authorisation to repurchase and transfer shares
The Board of Directors was authorised to decide to repurchase or accept as pledge up to 2,500,000 own shares of the company using the company's unrestricted shareholders' equity. The repurchase can take place in one or several lots. The authorisation will be in force until the end of the next Annual General Meeting. The authorisation cancels the previous authorisation granted by the Annual General Meeting of 31 March 2016 to the Board of Directors for the repurchase of own shares.
The Board of Directors was authorized to decide on a share issue and an issue of special rights entitling to shares as referred to in Chapter 10, section 1 of the Limited Liability Companies Act. Based on the authorisation, the Board is entitled to issue no more than 12,000,000 new shares or own shares held by the company, in one or several lots. The maximum number proposed corresponds to around 9 per cent of all the company's current shares.
The share issue may also be a directed issue in deviation from the shareholders' pre-emptive rights. The authorisation can be used to implement mergers and acquisitions, to develop the company's capital structure, in the company's incentive schemes, to pay potential share-based rewards to Board members and to other purposes decided by the Board. The Board is authorised to decide on all other terms and conditions of the share issue and of the issue of special rights entitling to shares.
The authorisation will be in force until the end of the next Annual General Meeting. The authorisation cancels the authorisations granted to the Board of Directors by the Annual General Meeting of 31 March 2016 and the Extraordinary General Meeting of 25 October 2016 to decide on a share issue and an issue of special rights entitling to shares.
Distribution: Nasdaq Helsinki Key media www.dna.fi
More information:
DNA Corporate Communications, tel. + 044 044 8000 communications@dna.fi Marja Mäkinen, Investor Relations, tel +358 (0)44 044 1262, marja.makinen@dna.fi
DNA Plc is a Finnish telecommunications group providing high-quality voice, data and TV services for communication, entertainment and working. DNA is Finland's largest cable operator and the leading pay TV provider in both cable and terrestrial networks. For DNA, the key area for growth in corporate business is the new way of working, independent of time and place, facilitated by smart terminal devices, diverse communications services and rapid connections. In 2016, DNA recorded net sales of EUR 859 million and an operating profit of EUR 91 million. DNA has more than 3.8 million subscriptions in its fixed and mobile communications networks. The Group also includes DNA Store, Finland's largest retail chain selling mobile phones. DNA shares are listed on Nasdaq Helsinki Ltd. For further information, visit www.dna.fi or follow us on Twitter @DNA_fi, @DNA_Business and @DNA_Palvelu and Facebook.
